Enliven Therapeutics (NASDAQ:ELVN) COO Sells $140,056.26 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,663 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $21.02, for a total value of $140,056.26. Following the completion of the sale, the chief operating officer directly owned 263,311 shares of the company’s stock, valued at approximately $5,534,797.22. This represents a 2.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Anish Patel also recently made the following trade(s):

• On Friday, November 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $17.40, for a total value of $116,005.80.
• On Tuesday, October 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.10, for a total value of $134,006.70.

Enliven Therapeutics Stock Down 10.2%

NASDAQ ELVN opened at $16.86 on Friday. The business’s fifty day simple moving average is $20.79 and its 200-day simple moving average is $20.42. The firm has a market cap of $1.00 billion, a PE ratio of -9.16 and a beta of 0.35. Enliven Therapeutics, Inc. has a 52 week low of $13.30 and a 52 week high of $25.37.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. Research analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Enliven Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $41.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ELVN. Quantbot Technologies LP acquired a new stake in shares of Enliven Therapeutics in the first quarter valued at $60,000. BNP Paribas Financial Markets boosted its holdings in Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares during the period. AlphaQuest LLC acquired a new position in Enliven Therapeutics in the 3rd quarter valued at about $96,000. Tower Research Capital LLC TRC increased its stake in Enliven Therapeutics by 194.3% during the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after purchasing an additional 3,490 shares during the period. Finally, KLP Kapitalforvaltning AS lifted its position in shares of Enliven Therapeutics by 58.1% during the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock worth $136,000 after purchasing an additional 2,500 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.